Loading interface...

Oncotar 100 mg Injection

Manufactured byUnited Biotech Pvt. Ltd.
ContainsCytarabine
Description

Oncotar 100 mg Injection is an anti-cancer medicine which is used in the treatment of various types of blood cancers such as Acute non-lymphocytic leukemia and Acute lymphocytic leukemia. It should be used under the supervision of a qualified physician. Close monitoring of liver function and blood cell count are necessary while receiving this medication.

Side effects

Major & minor side effects for Oncotar 100 mg Injection

  • Nausea
  • Vomiting
  • Diarrhea
  • Rash
  • Fever
  • Elevated Liver Enzymes
  • Bleeding
  • Headache
  • Chest pain
  • Joint pain

Uses of Oncotar 100 mg Injection

What is it prescribed for?

  • Acute Lymphocytic Leukemia
  • Acute Non Lymphocytic Leukemia
Read More
Concerns

Commonly asked questions

  • How long does it take for this medicine to take effect?
    The amount of time required for this medicine to show its action is not clinically established.
  • How long do the effects of this medicine last?
    The amount of time for which this medicine remains active in the body is not clinically established.
  • Is it safe to consume alcohol while taking this medicine?
    Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
  • Is this a habit forming medicine?
    No habit-forming tendencies were reported.
  • Can this medicine be taken during pregnancy?
    This medicine is not recommended for use in pregnant women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine.
  • Can this medicine be taken while breast-feeding?
    This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine.

Allergy

This medicine is not recommended for use in patients with a known allergy to cytarabine, or any other inactive ingredients present in the formulation.
Warnings for special population

Pregnancy

This medicine is not recommended for use in pregnant women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine.

Breast-feeding

This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine.
General warnings

Use in Elderly

This medicine should be used with caution in elderly patients. Your physician will make the appropriate dose adjustments or replacement with a suitable alternative medicine based on the clinical condition and therapeutic response.

Liver Disease

This medicine should be used with caution in patients with liver diseases due to the increased risk of adverse effects. Regular monitoring of liver function tests is necessary for such patients. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.

Driving or Operating machinery

Use of this medicine may rarely cause dizziness in some patients. It is advised that you do not perform any activities such as driving a vehicle or operating machinery if you experience any dizziness during treatment with this medicine.

Bone marrow suppression

This medicine should be used with caution since it may increase the risk of myelosuppression (decreased bone marrow function). Regular monitoring of blood cells count is necessary while receiving this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.

Missed Dose

Since this medicine is usually administered by a qualified healthcare professional in the clinical/hospital setting, the likelihood of a missed dose is very low.

Overdose

Since this medicine is administered in the hospital setting by a qualified healthcare professional, the likelihood of an overdose is very less. However, emergency medical treatment will be initiated by the doctor if an overdose is suspected.
All drugs interact differently for person to person. You should check all the possible interactions with your doctor before starting any medicine.
Interaction with Alcohol

Description

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

Instructions

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
Interaction with Medicine

Thalidomide

Adalimumab

Digoxin

Methotrexate

Cyclophosphamide

Naltrexone

Vinblastine

Disease interactions

Infections

This medicine should be used with extreme caution in patients with a history of recurrent infections due to the increased risk of myelosuppression. Initiation of therapy with this medicine in patients with active infections is not recommended. Patients susceptible to infections should be monitored closely during treatment with this medicine. An alternative treatment option may be necessary in some cases based on the clinical condition.
Food interactions
Information not available.
Lab interactions
Information not available.
This medicine is usually administered in the clinical/hospital setting under the supervision of a qualified healthcare professional. Follow all the instructions given by your doctor. Inform the doctor if you have a known allergy to this medicine. Report all your current medicines as well as your medical conditions to the doctor before receiving this medicine.
Miscelleneous

Usage does not depend on food timings

To be taken as instructed by doctor

May cause sleepiness

How it works
This medicine prevents the growth and spread of cancer cells in the body.
Legal Status

Approved

Approved

Approved

Approved

Classification

Category

Antimetabolites

Schedule

Schedule H

[Internet]. Pfizer.com. 2018 [cited 11 December 2018]. Available from:

https://www.pfizer.com/sites/default/files/products/uspi_cytarabine_1000mg.pdf

Cytarabine Injection Solution 100 mg/ml - Summary of Product Characteristics (SmPC) - (eMC) [Internet]. Medicines.org.uk. 2018 [cited 11 December 2018]. Available from:

https://www.medicines.org.uk/emc/product/1570/smpc#INTERACTIONS

TGA eBS - Product and Consumer Medicine Information Licence [Internet]. Ebs.tga.gov.au. 2018 [cited 11 December 2018]. Available from:

https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-06989-3&d=201812111016933

Cytarabine - DrugBank [Internet]. Drugbank.ca. 2018 [cited 11 December 2018]. Available from:

https://www.drugbank.ca/drugs/DB00987
Loading related questions...
Something doesn’t feel right?
Report an error

Information on this page was last updated on 29 Aug 2019

Disclaimer

We’ve made all possible efforts to ensure that the information provided here is accurate, up-to-date and complete, however, it should not be treated as a substitute for professional medical advice, diagnosis or treatment. Practo only provides reference source for common information on medicines and does not guarantee its accuracy or exhaustiveness. The absence of a warning for any drug or combination thereof, should not be assumed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Practo does not assume any responsibility for any aspect of healthcare administered with the aid of information provided above. If you have any doubts about your medication then we strongly recommend that you consult with your doctor, nurse or healthcare provider. See detailed T&C here.